Federal Circuit affirms Humira licence decision
06-02-2018
Inventiva and AbbVie extend agreement to develop RORγ inverse agonists
04-09-2017
AbbVie has lost in an inter partes review (IPR) of its rheumatoid arthritis drug Humira (adalimumab).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AbbVie, Coherus, patent, IPR, Humira, PTAB,
